Remdesivir for the Treatment of SARS-CoV-2 - Creative Biolabs

Remdesivir is a new prodrug that is a nucleotide analog that has broad-spectrum antiviral activity. Its development code is GS-5734. In a number of animal models, it has been shown to be a promising antiviral medication against a broad range of RNA viruses, such as SRAS and MERS. Remdesivir functions as an adenosine analogue, integrating into developing viral RNA chains to cause premature termination. Furthermore, the research has demonstrated that remdesivir effectively prevents virus infection in Huh-7 human liver cancer cells, which are susceptible to SARS-CoV-2. Remdesivir's EC90 value against SARS-CoV-2 in Vero E6 cells was 1.76 μM, according to the assay data, indicating that nonhuman primates (NHPs) are likely to be able to obtain its working concentration.